{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:01:03Z","timestamp":1785409263416,"version":"3.56.0"},"reference-count":7,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>The Phase III ODYSSEY-HCM trial evaluating the cardiac myosin inhibitor mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy did not demonstrate significant improvements in clinical endpoints, including the Kansas City Cardiomyopathy Questionnaire score and peak oxygen consumption. However, mavacamten significantly reduced pro-B-type natriuretic peptide levels and improved echocardiographic indices of diastolic and left atrial function, suggesting a potential biological effect. This apparent dissociation between biomarker improvement and clinical outcomes raises questions regarding patient selection, endpoint choice and dosing strategy. In addition, the observed decline in left ventricular systolic function in a substantial proportion of treated patients may have offset the benefits of improved diastolic performance and may have implications for arrhythmic vulnerability. In this viewpoint, the ODYSSEY-HCM trial is critically appraised and future directions for optimising myosin inhibition therapy in non-obstructive hypertrophic cardiomyopathy are discussed.<\/jats:p>","DOI":"10.15420\/ecr.2026.17","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T18:19:13Z","timestamp":1781029153000},"source":"Crossref","is-referenced-by-count":0,"title":["Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM"],"prefix":"10.15420","author":[{"given":"Koji","family":"Hasegawa","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/045kb1d14","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritake","family":"Iguchi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/045kb1d14","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Wada","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/045kb1d14","id-type":"ROR","asserted-by":"publisher"}],"name":"Kyoto Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe-Andrei","family":"Dan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04fm87419","id-type":"ROR","asserted-by":"publisher"}],"name":"Carol Davila University of Medicine and Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Braunwald E. Hypertrophic cardiomyopathy. N Engl J Med 2025;393:1004\u201315. https:\/\/doi.org\/10.1056\/NEJMra2413445; PMID: 40888703. DOI: 10.1056\/NEJMra2413445","DOI":"10.1056\/NEJMra2413445"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Braunwald E, Saberi S, Abraham TP, et al. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehad637; PMID: 37804245. DOI: 10.1093\/eurheartj\/ehad637","DOI":"10.1093\/eurheartj\/ehad637"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2020;75:2649\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.064; PMID: 32466879. DOI: 10.1016\/j.jacc.2020.03.064","DOI":"10.1016\/j.jacc.2020.03.064"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Desai MY, Owens AT, Abraham T, et al. Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. N Engl J Med 2025;393:961\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2505927; PMID: 40888717. DOI: 10.1056\/NEJMoa2505927","DOI":"10.1056\/NEJMoa2505927"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J 2013;34:2529\u201337. https:\/\/doi.org\/10.1093\/eurheartj\/eht070; PMID: 23455360. DOI: 10.1093\/eurheartj\/eht070","DOI":"10.1093\/eurheartj\/eht070"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kehl DW, Buttan A, Siegel RJ, Rader F. Clinical utility of natriuretic peptides and troponins in hypertrophic cardiomyopathy. Int J Cardiol 2016;218:252\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2016.05.031; PMID: 27236124. DOI: 10.1016\/j.ijcard.2016.05.031","DOI":"10.1016\/j.ijcard.2016.05.031"},{"key":"ref6","unstructured":"Desai MY, Okushi Y, Jadam S, et al. Echocardiographic changes with mavacamten in nonobstructive hypertrophic cardiomyopathy: exploratory insights from the Odyssey-HCM trial. J Am Coll Cardiol 2025;86:2434\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.019; PMID: 40864019."}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:36:56Z","timestamp":1781519816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":7,"URL":"https:\/\/doi.org\/10.15420\/ecr.2026.17","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"e31"}}